LT2964229T - Histamino h4 receptoriaus benzoimidazol-2-ilpirimidino moduliatoriai - Google Patents
Histamino h4 receptoriaus benzoimidazol-2-ilpirimidino moduliatoriaiInfo
- Publication number
- LT2964229T LT2964229T LTEP14760540.6T LT14760540T LT2964229T LT 2964229 T LT2964229 T LT 2964229T LT 14760540 T LT14760540 T LT 14760540T LT 2964229 T LT2964229 T LT 2964229T
- Authority
- LT
- Lithuania
- Prior art keywords
- benzoimidazol
- histamine
- receptor
- modulators
- pyrimidine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
- C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
- C30B29/54—Organic compounds
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
- C30B7/08—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by cooling of the solution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Crystallography & Structural Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Neurology (AREA)
- Materials Engineering (AREA)
- Metallurgy (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biotechnology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361773706P | 2013-03-06 | 2013-03-06 | |
US201361776260P | 2013-03-11 | 2013-03-11 | |
US201361784909P | 2013-03-14 | 2013-03-14 | |
PCT/US2014/021130 WO2014138368A1 (en) | 2013-03-06 | 2014-03-06 | Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor |
Publications (1)
Publication Number | Publication Date |
---|---|
LT2964229T true LT2964229T (lt) | 2020-02-10 |
Family
ID=51488591
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEP14760540.6T LT2964229T (lt) | 2013-03-06 | 2014-03-06 | Histamino h4 receptoriaus benzoimidazol-2-ilpirimidino moduliatoriai |
Country Status (38)
Country | Link |
---|---|
US (4) | US8859575B2 (lt) |
EP (2) | EP2964229B1 (lt) |
JP (1) | JP6471103B2 (lt) |
KR (1) | KR102230383B1 (lt) |
CN (1) | CN105025898B (lt) |
AU (1) | AU2014225675B2 (lt) |
BR (1) | BR112015021463A8 (lt) |
CA (1) | CA2903737C (lt) |
CL (1) | CL2015002434A1 (lt) |
CR (1) | CR20150435A (lt) |
CY (1) | CY1122545T1 (lt) |
DK (1) | DK2964229T3 (lt) |
DO (1) | DOP2016000027A (lt) |
EA (1) | EA201591648A1 (lt) |
ES (1) | ES2773543T3 (lt) |
GT (1) | GT201500243A (lt) |
HK (1) | HK1218513A1 (lt) |
HR (1) | HRP20200253T1 (lt) |
HU (1) | HUE047681T2 (lt) |
IL (1) | IL240247B (lt) |
JO (1) | JO3516B1 (lt) |
LT (1) | LT2964229T (lt) |
MX (1) | MX2015011688A (lt) |
MY (1) | MY180726A (lt) |
NZ (1) | NZ710640A (lt) |
PE (1) | PE20151536A1 (lt) |
PH (1) | PH12015501731A1 (lt) |
PL (1) | PL2964229T3 (lt) |
PT (1) | PT2964229T (lt) |
RS (1) | RS59909B1 (lt) |
SA (1) | SA515360981B1 (lt) |
SG (1) | SG11201507117XA (lt) |
SI (1) | SI2964229T1 (lt) |
TW (1) | TWI617554B (lt) |
UA (1) | UA118754C2 (lt) |
UY (1) | UY35370A (lt) |
WO (1) | WO2014138368A1 (lt) |
ZA (1) | ZA201507351B (lt) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS51423B (en) | 2006-03-31 | 2011-02-28 | Janssen Pharmaceutica N.V. | BENZOIMIDAZOL-2-IL PYRIMIDINI I KAO PYRAZID MODULATORS HISTAMINSKOG H4 RECEPTOR |
US9371311B2 (en) | 2008-06-30 | 2016-06-21 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyrimidine derivatives |
MX2015011688A (es) | 2013-03-06 | 2015-12-07 | Janssen Pharmaceutica Nv | Moduladores benzoimidazol-2-il pirimidinas del receptor h4 de histamina. |
TWI644671B (zh) | 2013-03-14 | 2018-12-21 | 比利時商健生藥品公司 | P2x7調節劑 |
US9040534B2 (en) | 2013-03-14 | 2015-05-26 | Janssen Pharmaceutica Nv | [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators |
TWI627174B (zh) | 2013-03-14 | 2018-06-21 | 比利時商健生藥品公司 | P2x7調控劑 |
EP3321266A1 (en) | 2013-03-14 | 2018-05-16 | Janssen Pharmaceutica NV | P2x7 modulators |
EA034015B1 (ru) | 2014-09-12 | 2019-12-19 | Янссен Фармацевтика Нв | Модуляторы р2х7 |
AU2017394032B8 (en) | 2017-01-21 | 2020-10-22 | Guangzhou Hanfang Pharmaceutical Co., Ltd. | Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome |
JP7413368B2 (ja) | 2018-09-28 | 2024-01-15 | ヤンセン ファーマシューティカ エヌ.ベー. | モノアシルグリセロールリパーゼ調節因子 |
CN113164459B (zh) | 2018-09-28 | 2024-09-03 | 詹森药业有限公司 | 单酰基甘油脂肪酶调节剂 |
JP2022550767A (ja) | 2019-09-30 | 2022-12-05 | ヤンセン ファーマシューティカ エヌ.ベー. | 放射線標識されたmgl petリガンド |
KR20220157999A (ko) | 2020-03-26 | 2022-11-29 | 얀센 파마슈티카 엔.브이. | 모노아실글리세롤 리파아제 조절제 |
Family Cites Families (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3005852A (en) | 1959-12-22 | 1961-10-24 | Gen Aniline & Film Corp | Production of sulfoxides and sulfones |
GB1062357A (en) | 1965-03-23 | 1967-03-22 | Pfizer & Co C | Quinazolone derivatives |
US3931195A (en) | 1971-03-03 | 1976-01-06 | Mead Johnson & Company | Substituted piperidines |
US4191828A (en) | 1976-04-14 | 1980-03-04 | Richardson-Merrell Inc. | Process for preparing 2-(2,2-dicyclohexylethyl)piperidine |
US4337341A (en) | 1976-11-02 | 1982-06-29 | Eli Lilly And Company | 4a-Aryl-octahydro-1H-2-pyrindines |
US4190601A (en) | 1978-05-31 | 1980-02-26 | Union Carbide Corporation | Production of tertiary amines by reductive alkylation |
JPS6130576A (ja) | 1984-07-24 | 1986-02-12 | Ube Ind Ltd | 2−アミノ−5−シアノピリミジンの製法 |
GB9410031D0 (en) | 1994-05-19 | 1994-07-06 | Merck Sharp & Dohme | Therapeutic agents |
GB9422391D0 (en) | 1994-11-05 | 1995-01-04 | Solvay Interox Ltd | Oxidation of organosulphur compounds |
JPH10510540A (ja) | 1994-12-12 | 1998-10-13 | オメロス メディカル システムズ,インコーポレーテッド | 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法 |
US5883105A (en) | 1996-04-03 | 1999-03-16 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
CA2250936A1 (en) | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
EP0891351A1 (en) | 1996-04-03 | 1999-01-20 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5880140A (en) | 1996-04-03 | 1999-03-09 | Merck & Co., Inc. | Biheteroaryl inhibitors of farnesyl-protein transferase |
US5939439A (en) | 1996-12-30 | 1999-08-17 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
WO1998031369A1 (fr) | 1997-01-16 | 1998-07-23 | Sekisui Chemical Co., Ltd. | Preparations a usage externe a absorption percutanee |
AU729869B2 (en) | 1997-01-17 | 2001-02-15 | Merck & Co., Inc. | Integrin antagonists |
US5945422A (en) | 1997-02-05 | 1999-08-31 | Warner-Lambert Company | N-oxides of amino containing pyrido 2,3-D! pyrimidines |
AU724216B2 (en) | 1997-04-07 | 2000-09-14 | Merck & Co., Inc. | A method of treating cancer |
GB9801231D0 (en) | 1997-06-05 | 1998-03-18 | Merck & Co Inc | A method of treating cancer |
AU9663798A (en) | 1997-10-06 | 1999-04-27 | Warner-Lambert Company | Heteroaryl butyric acids and their derivatives as inhibitors of matrix metalloproteinases |
ATE245641T1 (de) | 1998-02-17 | 2003-08-15 | Tularik Inc | Antivirale pyrimidinderivate |
EP1087963B1 (en) | 1998-06-19 | 2004-08-25 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
ATE242241T1 (de) | 1999-03-25 | 2003-06-15 | Synthon Bv | Imidazopyridinderivate und verfahren zu ihrer herstellung |
NZ516348A (en) | 1999-06-23 | 2003-06-30 | Aventis Pharma Gmbh | Substituted benzimidazole |
TWI279402B (en) | 1999-08-20 | 2007-04-21 | Banyu Pharma Co Ltd | Spiro compounds having NPY antagonistic activities and agents containing the same |
HUP0202678A3 (en) | 1999-09-30 | 2004-06-28 | Pfizer | Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines, pharmaceutical compositions containing them and their use |
CN1623984A (zh) | 1999-12-27 | 2005-06-08 | 日本烟草产业株式会社 | 稠环化合物及其药物用途 |
DE10006453A1 (de) | 2000-02-14 | 2001-08-16 | Bayer Ag | Piperidylcarbonsäuren als Integrinantagonisten |
CN1592621A (zh) * | 2000-04-24 | 2005-03-09 | 特瓦制药工业有限公司 | 唑吡坦半酒石酸盐 |
DE60125429T2 (de) * | 2000-04-24 | 2007-09-27 | Teva Pharmaceutical Industries Ltd. | Zolpidem hemitartrat solvat |
EP1296977A1 (en) | 2000-06-23 | 2003-04-02 | Bristol-Myers Squibb Pharma Company | Heteroaryl-phenyl substituted factor xa inhibitors |
AU2001289615A1 (en) | 2000-06-28 | 2002-01-08 | Thromb-X N.V. | Pluripotent embryonic stem (es) cell lines, improved methods for their production, and their use for germ line transmission and for the generation of genetically modified animals |
BR0112712A (pt) | 2000-07-21 | 2003-05-20 | Syngenta Partcipations Ag | Processo para preparação de 4,6-dimetóxi-2-(metilsulfonil)-1,3-pirimidina |
KR100816769B1 (ko) | 2000-09-06 | 2008-03-26 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 글리코겐 합성효소 키나아제 3의 억제제 |
CA2430037A1 (en) | 2000-11-20 | 2002-05-30 | Michael S. South | Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade |
WO2002064096A2 (en) | 2001-02-16 | 2002-08-22 | Tularik Inc. | Methods of using pyrimidine-based antiviral agents |
US6803362B2 (en) | 2001-03-09 | 2004-10-12 | Ortho-Mcneil Pharmaceutical Inc. | Heterocyclic compounds |
AU2002247402A1 (en) | 2001-03-23 | 2002-10-08 | Chugai Seiyaku Kabushiki Kaisha | Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis |
US20050107400A1 (en) | 2001-03-30 | 2005-05-19 | Boyd Leslie F. | Use of pyrazolopyridines as therapeutic compounds |
US6858600B2 (en) | 2001-05-08 | 2005-02-22 | Yale University | Proteomimetic compounds and methods |
AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
US7141572B2 (en) * | 2001-11-05 | 2006-11-28 | Merck Patent Gesellschaft | Hydrazono-malonitriles |
US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
US7148236B2 (en) | 2002-01-17 | 2006-12-12 | Merck & Co., Inc. | Modulators of acetylcholine receptors |
TWI270542B (en) | 2002-02-07 | 2007-01-11 | Sumitomo Chemical Co | Method for preparing sulfone or sulfoxide compound |
US7314937B2 (en) | 2002-03-21 | 2008-01-01 | Eli Lilly And Company | Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses |
WO2004012736A1 (en) | 2002-08-02 | 2004-02-12 | Genesoft Pharmaceuticals, Inc. | Biaryl compounds having anti-infective activity |
EP1551406A1 (en) | 2002-09-06 | 2005-07-13 | Janssen Pharmaceutica N.V. | Use of indolyl derivatives for the manufacture of a medicament for the treatment of allergic rhinitis |
US20040127395A1 (en) | 2002-09-06 | 2004-07-01 | Desai Pragnya J. | Use of histamine H4 receptor modulators for the treatment of allergy and asthma |
DE60305052T2 (de) | 2002-09-06 | 2006-12-21 | Janssen Pharmaceutica N.V. | Thienopyrrolyl und furanopyrrolyl verbindungen und deren verwendung als histamin h4 rezeptor liganden |
CA2497827A1 (en) | 2002-09-06 | 2004-03-18 | Janssen Pharmaceutica, N.V. | (1h-benzoimidazol-2-yl)-(piperazinyl)-methanone derivatives and related compounds as histamine h4-receptor antagonists for the treatment of inflammatory and allergic disorders |
EP1546115A4 (en) | 2002-09-27 | 2010-08-04 | Merck Sharp & Dohme | SUBSTITUTED PYRIMIDINES |
TW200501960A (en) | 2002-10-02 | 2005-01-16 | Bristol Myers Squibb Co | Synergistic kits and compositions for treating cancer |
US20040105856A1 (en) | 2002-12-02 | 2004-06-03 | Robin Thurmond | Use of histamine H4 receptor antagonist for the treatment of inflammatory responses |
BRPI0409986A (pt) | 2003-05-05 | 2006-05-09 | Hoffmann La Roche | derivados de pirimidina fundida com atividade de crf |
KR20060023529A (ko) | 2003-05-14 | 2006-03-14 | 토레이파인스 테라퓨틱스, 인코포레이티드 | 화합물 및 아밀로이드 베타를 변조하는데 있어서 그의 용도 |
SE0302116D0 (sv) | 2003-07-21 | 2003-07-21 | Astrazeneca Ab | Novel compounds |
MXPA05013637A (es) | 2003-08-13 | 2006-02-24 | Chiron Corp | Inhibidores gsk-3 y usos de los mismos. |
BRPI0414581C1 (pt) | 2003-09-22 | 2021-05-25 | Mei Pharma Inc | composto, composição farmacêutica compreendendo o referido composto e uso do referido composto |
CA2540638A1 (en) | 2003-09-30 | 2005-04-14 | Janssen Pharmaceutica N.V. | Quinoxaline compounds |
US7432378B2 (en) | 2003-09-30 | 2008-10-07 | Janssen Pharmaceutica, N.V. | Benzoimidazole compounds |
WO2005032490A2 (en) | 2003-10-08 | 2005-04-14 | Bristol-Myers Squibb Company | Cyclic diamines and derivatives as factor xa inhibitors |
JPWO2005040135A1 (ja) | 2003-10-24 | 2007-03-08 | 小野薬品工業株式会社 | 抗ストレス薬およびその医薬用途 |
US8277831B2 (en) | 2004-02-17 | 2012-10-02 | Advanced Technologies And Regenerative Medicine, Llc. | Drug-enhanced adhesion prevention |
CA2560896C (en) | 2004-03-25 | 2013-06-18 | Janssen Pharmaceutica, N.V. | Imidazole compounds |
JPWO2005115993A1 (ja) | 2004-05-31 | 2008-03-27 | 萬有製薬株式会社 | キナゾリン誘導体 |
ES2362102T3 (es) | 2004-06-30 | 2011-06-28 | Janssen Pharmaceutica Nv | Eteres de bencimidazol e imidazopiridina sustituidos con arilo como agentes anticáncer. |
EP1790650B1 (en) | 2004-08-31 | 2014-03-26 | Msd Kk | NEW SUBSTITUTED IMIDAZOLE DERIVATIVES |
US7906528B2 (en) | 2004-10-05 | 2011-03-15 | Novartis International Pharmaceutical Ltd. | Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds |
US7381732B2 (en) | 2004-10-26 | 2008-06-03 | Bristol-Myers Squibb Company | Pyrazolobenzamides and derivatives as factor Xa inhibitors |
US7442716B2 (en) | 2004-12-17 | 2008-10-28 | Merck Frosst Canada Ltd. | 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors |
CN101119973B (zh) | 2004-12-17 | 2011-08-03 | 默克弗罗斯特加拿大有限公司 | 作为mPGES-1抑制剂的2-(苯基或者杂环基)-1H-菲并[9,10-d]咪唑类化合物 |
AU2006226775A1 (en) | 2005-03-24 | 2006-09-28 | Janssen Pharmaceutica, N.V. | Biaryl derived amide modulators of vanilloid VR1 receptor |
WO2007044085A2 (en) | 2005-05-19 | 2007-04-19 | Xenon Pharmaceuticals Inc. | Heteroaryl compounds and their uses as therapeutic agents |
US8193206B2 (en) | 2005-06-14 | 2012-06-05 | Taigen Biotechnology Co., Ltd. | Pyrimidine compounds |
US20060281712A1 (en) | 2005-06-14 | 2006-12-14 | Chi-Feng Yen | Pyrimidine compounds |
MX2007015675A (es) | 2005-07-04 | 2008-02-20 | Novo Nordisk As | Antagonistas del receptor de histamina h3. |
BRPI0615880A2 (pt) | 2005-09-13 | 2011-05-31 | Palau Pharma Sa | compostos derivados de 2-aminopirimidina como moduladores da atividade de receptor da histamina h4, uso dos mesmos e composição farmacêutica |
AR056560A1 (es) | 2005-10-06 | 2007-10-10 | Astrazeneca Ab | Pirrolopiridinonas como moduladores cb1 |
EP1954287B2 (en) | 2005-10-31 | 2016-02-24 | Merck Sharp & Dohme Corp. | Cetp inhibitors |
US20090182142A1 (en) | 2005-12-02 | 2009-07-16 | Shigeru Furukubo | Aromatic Compound |
US20090286772A1 (en) | 2006-02-24 | 2009-11-19 | Anh Chau | 2-(Phenyl or Heterocyclic)-1H-Phenanthro[9,10-D]Imidazoles |
EP2004188B1 (en) | 2006-03-31 | 2010-09-01 | Janssen Pharmaceutica NV | Benzoimidazol-2-yl pyridines as modulators of the histamine h4 receptor |
RS51423B (en) | 2006-03-31 | 2011-02-28 | Janssen Pharmaceutica N.V. | BENZOIMIDAZOL-2-IL PYRIMIDINI I KAO PYRAZID MODULATORS HISTAMINSKOG H4 RECEPTOR |
JP5132673B2 (ja) | 2006-04-07 | 2013-01-30 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒスタミンh4受容体のモジュレーターとしてのインドールおよびベンゾイミダゾール |
US20090069343A1 (en) | 2006-04-10 | 2009-03-12 | Dunford Paul J | Combination Histamine H1R and H4R Antagonist Therapy for Treating Pruritus |
US20090192158A1 (en) | 2006-05-02 | 2009-07-30 | Stacia Kargman | Methods for Treating or Preventing Neoplasias |
US20090209571A1 (en) | 2006-05-18 | 2009-08-20 | Bernard Cote | Phenanthrene derivatives as MPGES-1 inhibitors |
CL2007002007A1 (es) | 2006-07-11 | 2008-08-22 | Janssen Pharmaceutica Nv | Compuestos derivados de benzofuro y benzotienopirimidinas, moduladores del receptor de histamina h4; procedimiento de preparacion; y su uso para tratar trastornos inflamatorios, alergicos, dermatologicos, enfermedades autoinmune, linfaticas y de inmu |
US8779154B2 (en) * | 2006-09-26 | 2014-07-15 | Qinglin Che | Fused ring compounds for inflammation and immune-related uses |
TW200904437A (en) | 2007-02-14 | 2009-02-01 | Janssen Pharmaceutica Nv | 2-aminopyrimidine modulators of the histamine H4 receptor |
AR069480A1 (es) | 2007-11-30 | 2010-01-27 | Palau Pharma Sa | Derivados de 2-amino-pirimidina |
WO2009079001A1 (en) | 2007-12-18 | 2009-06-25 | Janssen Pharmaceutica N.V. | Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine h4 receptor |
PE20110061A1 (es) | 2008-06-12 | 2011-01-31 | Janssen Pharmaceutica Nv | Derivados de diamino-piridina, pirimidina y piridazina como moduladores del receptor h4 de histamina |
CA2727627C (en) | 2008-06-12 | 2018-02-13 | Janssen Pharmaceutica Nv | Use of histamine h4 antagonist for the treatment of post-operative adhesions |
ES2538135T3 (es) | 2008-06-30 | 2015-06-17 | Janssen Pharmaceutica N.V. | Proceso para la preparación de derivados sustituidos de pirimidina |
BRPI0913989A2 (pt) * | 2008-06-30 | 2015-10-20 | Janssen Pharmaceutica Nv | processo para preparação de derivados de benzoimidazol-2-il pirirmidina |
WO2010025314A2 (en) * | 2008-08-28 | 2010-03-04 | The General Hospital Corporation | Prevention and treatment of itch with cysteine protease inhibition |
IT1395963B1 (it) * | 2009-06-04 | 2012-11-02 | Rottapharm Spa | Forme cristalline di 6-(1h-imidazol-1-il)-2-fenil chinazolina e dei suoi sali |
TWI519533B (zh) | 2010-11-01 | 2016-02-01 | Lg生命科學有限公司 | 1-{(2S)-2-胺基-4-[2,4-雙(三氟甲基)-5,8-二氫吡啶并[3,4-d]嘧啶-7(6H)-基]-4-側氧丁基}-5,5-二氟哌啶-2-酮酒石酸鹽之水合物 |
EP2465498A1 (en) * | 2010-11-23 | 2012-06-20 | Faes Farma, S.A. | Diphenyl-amine derivatives: uses, process of synthesis and pharmaceutical compositions |
MX2015011688A (es) | 2013-03-06 | 2015-12-07 | Janssen Pharmaceutica Nv | Moduladores benzoimidazol-2-il pirimidinas del receptor h4 de histamina. |
-
2014
- 2014-03-06 MX MX2015011688A patent/MX2015011688A/es active IP Right Grant
- 2014-03-06 AU AU2014225675A patent/AU2014225675B2/en not_active Ceased
- 2014-03-06 US US14/199,634 patent/US8859575B2/en active Active
- 2014-03-06 MY MYPI2015702907A patent/MY180726A/en unknown
- 2014-03-06 KR KR1020157026804A patent/KR102230383B1/ko active IP Right Grant
- 2014-03-06 EA EA201591648A patent/EA201591648A1/ru unknown
- 2014-03-06 JO JOP/2014/0074A patent/JO3516B1/ar active
- 2014-03-06 WO PCT/US2014/021130 patent/WO2014138368A1/en active Application Filing
- 2014-03-06 TW TW103107723A patent/TWI617554B/zh not_active IP Right Cessation
- 2014-03-06 NZ NZ710640A patent/NZ710640A/en not_active IP Right Cessation
- 2014-03-06 PT PT147605406T patent/PT2964229T/pt unknown
- 2014-03-06 JP JP2015561646A patent/JP6471103B2/ja not_active Expired - Fee Related
- 2014-03-06 LT LTEP14760540.6T patent/LT2964229T/lt unknown
- 2014-03-06 UY UY0001035370A patent/UY35370A/es unknown
- 2014-03-06 DK DK14760540.6T patent/DK2964229T3/da active
- 2014-03-06 PL PL14760540T patent/PL2964229T3/pl unknown
- 2014-03-06 SI SI201431440T patent/SI2964229T1/sl unknown
- 2014-03-06 BR BR112015021463A patent/BR112015021463A8/pt not_active Application Discontinuation
- 2014-03-06 HU HUE14760540A patent/HUE047681T2/hu unknown
- 2014-03-06 EP EP14760540.6A patent/EP2964229B1/en active Active
- 2014-03-06 EP EP19213615.8A patent/EP3660011A1/en not_active Withdrawn
- 2014-03-06 CA CA2903737A patent/CA2903737C/en active Active
- 2014-03-06 SG SG11201507117XA patent/SG11201507117XA/en unknown
- 2014-03-06 CN CN201480012369.2A patent/CN105025898B/zh not_active Expired - Fee Related
- 2014-03-06 ES ES14760540T patent/ES2773543T3/es active Active
- 2014-03-06 RS RS20200160A patent/RS59909B1/sr unknown
- 2014-03-06 PE PE2015001832A patent/PE20151536A1/es not_active Application Discontinuation
- 2014-06-03 UA UAA201509634A patent/UA118754C2/uk unknown
- 2014-08-21 US US14/465,677 patent/US9278952B2/en not_active Expired - Fee Related
-
2015
- 2015-07-30 IL IL240247A patent/IL240247B/en active IP Right Grant
- 2015-08-06 PH PH12015501731A patent/PH12015501731A1/en unknown
- 2015-08-24 CR CR20150435A patent/CR20150435A/es unknown
- 2015-08-31 CL CL2015002434A patent/CL2015002434A1/es unknown
- 2015-09-02 GT GT201500243A patent/GT201500243A/es unknown
- 2015-09-03 SA SA515360981A patent/SA515360981B1/ar unknown
- 2015-10-05 ZA ZA2015/07351A patent/ZA201507351B/en unknown
-
2016
- 2016-01-22 DO DO2016000027A patent/DOP2016000027A/es unknown
- 2016-02-18 US US15/047,359 patent/US9434715B2/en active Active
- 2016-06-07 HK HK16106550.1A patent/HK1218513A1/zh unknown
- 2016-08-03 US US15/227,878 patent/US9663497B2/en active Active
-
2020
- 2020-02-03 CY CY20201100085T patent/CY1122545T1/el unknown
- 2020-02-14 HR HRP20200253TT patent/HRP20200253T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1218513A1 (zh) | 組胺 受體的苯並咪唑- -基嘧啶調節劑 | |
HK1214246A1 (zh) | 吲哚滿- -酮或吡咯並-吡啶/嘧啶- -酮衍生物 | |
PT3024827T (pt) | Derivados de quinazolin-4-ona substituídos | |
EP2946410A4 (en) | TECHNIQUES FOR FORMING OPTOELECTRONIC DEVICES | |
HK1213018A1 (zh) | 橋接雙環核苷 | |
EP3030233A4 (en) | Oxazole orexin receptor antagonists | |
HK1217294A1 (zh) | '- '- '-氟- '-甲基取代的核苷衍生物 | |
GB201303109D0 (en) | Novel pyrimidine compounds | |
PL2874772T3 (pl) | Kompensacyjny uchwyt zaciskowy | |
EP3072318A4 (en) | PROFILE INTEGRATION MANAGEMENT | |
EP2976077A4 (en) | BENZIMIDAZOLES SUBSTITUTED AS MODULATORS OF A NOCICEPTIN RECEPTOR | |
SG10201706775RA (en) | Optoelectronic component | |
EP2992165B8 (en) | Merlin drilling riser assembly | |
HK1223353A1 (zh) | 受體調節劑 | |
LT2989248T (lt) | Dekstrino pagrindo dengiamieji sluoksniai | |
EP2948625A4 (en) | OPTICAL DRILLING MEASUREMENT | |
EP2976864A4 (en) | RECOMMENDATIONS OF APPLICATION | |
EP3063664A4 (en) | Topic-wise collaboration integration | |
HK1223621A1 (zh) | 咪唑衍生物 | |
HK1219953A1 (zh) | 聯苯基-乙基-吡咯烷衍生物作為組胺 受體調節劑用於治療認知障礙 | |
HK1218647A1 (zh) | 血管加壓素- 受體激動劑 | |
EP3005147A4 (en) | Using aliases for date entry | |
GB201300061D0 (en) | Angular adjustment rig | |
GB201306013D0 (en) | compensation | |
GB201318284D0 (en) | Construction of surfaces |